Authors
Latest:
Leading Teams through the COVID-19 CrisisSuzanne Bates offers advice for leaders who are steering their teams through the current health crisis.
Latest:
Digital UpskillingArchaic ways of working need to make way for more agile and nimble response mechanisms enabled by a systematic enterprise-wide digital upskilling strategy, writes Anand Kiran.
Latest:
Design Thinking in Multichannel MarketingWhile marketers must work with less than perfect insight when devising their channel strategies, they can improve their success rate by applying Design Thinking, write Ilya Vedrashko and Parag More.
Latest:
COVID-19 Highlights Need for More Agility, New Paradigms in Drug DevelopmentThe rapid spread of COVID-19 across the globe highlights the absolute need for preparedness in the face of pandemics in order to reduce and eliminate the emergence of new cases and quickly create treatment options for emerging illnesses and diseases.
Latest:
How Medical Affairs Teams Need to Adapt to COVID-19COVID-19 will cause acute strain on medical affairs in the short term, but longer-term planning is also needed to ensure that teams can remain in the more visible role that customers are demanding, writes Sarah Jarvis.
Latest:
Patient Experience Breakthroughs: Leveraging the Latest Digital Tools and Techniques to Optimize your Patient Experience GoalsLearn how breakthrough patient experience strategies can help achieve your study goals in this upcoming webcast. Lead by renowned neuroscientist and behavioral economist Dr. Paul Glimcher, it’s the one webcast this year your team can’t afford to miss. Live: Tuesday, May 19, 2020 at 1pm EDT | 12pm CDT | 10am PDT On demand available after airing until May 19, 2021. Register free
Latest:
Solving Access Challenges in Today’s MarketNew drug launches face more marketplace scrutiny today than a decade ago. Brand success requires not only communicating the clinical value to providers and patients, but also demonstrating the cost-effectiveness to payers in a real-world setting.
Latest:
Fight Against COVID-19 May Yield Solutions to ARDSCombating ARDS, the biggest threat to COVID-19 patients, may lead to new treatments for the condition, writes physician and biotech CEO Joe G. N. “Skip” Garcia.
Latest:
How Biosimilar Manufacturers Can Get the Most Out of the "Patent Cliff"As the number of biologics facing patent expiration in the US continues to rise, the market is further opening up to biosimilar manufacturers. George I'ons offers some pointers on how to secure an attractive market share during this time.
Latest:
COVID-19 Therapeutics and Vaccines Are Here: What All Companies Need to Do NextThe pharmaceutical industry must be prepared for the coming wave of COVID-related safety reports.
Latest:
COVID-19: Risks for Pharma CommercializationIdentifying and acting on the risks developing in the major markets in light of COVID-19 disruption and the implications for assets in late-stage clinical development and early commercialization.
Latest:
COVID-19: Four Challenges for Issue Management TeamsDonna L. LaVoie discusses four key industry areas that will experience downstream pressures in the wake of the COVID-19 crisis.
Latest:
Sustaining Commercial Operations During a PandemicDan Schulman and Steve Trokenheim outline how life sciences companies can respond to the current crisis in measured ways to set them up for long-term success.
Latest:
End of Study Hacks: The New Digital AgeLearn from industry experts how to eliminate compliance risks associated with the up to 65% of sites that lose, never receive, or acknowledge these CDs/DVDs, along with the site audits where findings arise due to data access. Live: Thursday, May 7, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until May 7, 2021.
Latest:
The Power of Education in Treating Breast CancerBreast cancer is the most common cancer in women, and accounts for approximately 25% of all cancers in women worldwide.
Latest:
Field Perspective: A Collective View to inform the Future of Clinical ResearchTo really understand the issues and barriers preventing more efficient and effective clinical research, I went to the field to gather perspective from the core contributors.
Latest:
Quality More Important than Cost: Building the Business Case for PV AutomationAccording to new research, quality has overtaken cost as a priority in plans for automating adverse event reporting. John Price reveals the drivers and barriers to change.
Latest:
How Prepared Were Doctors for the COVID Digital Upswing?A new survey of healthcare professionals explores the pandemic-sparked shift in the adoption and acceptance of connected health technologies.
Latest:
How COVID-19 is Forcing Pharma to Adopt New Physician Interaction ModelsOver the coming months, HCPs and manufacturers will experiment with different approaches to e-detailing, in order to arrive at an approach that works for everyone, writes Scott Morano.
Latest:
COVID-19 and the Evolving Science of PharmacogenomicsInitial studies pointing to how genetic variations can impact disease states such as COVID-19 help to illustrate the growing importance of genomic medicine, writes Mark. J. Stevens.
